Intricon (IIN) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	INTRICON CORP
Entity Central Index Key	88,790
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		7,189,580

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 539	$ 373
Restricted cash	646	644
Accounts receivable, less allowance for doubtful accounts of $577 at June 30, 2018 and $332 at December 31, 2017	10,067	9,052
Inventories	15,644	13,708
Contract assets	6,032	2,979
Other current assets	1,760	1,544
Total current assets	34,688	28,300
Machinery and equipment	36,684	40,124
Less: Accumulated depreciation	27,531	32,949
Net machinery and equipment	9,153	7,175
Goodwill	10,808	10,808
Intangible assets, net	2,662	2,740
Investment in partnerships	1,865	1,616
Other assets, net	3,799	3,835
Total assets	62,975	54,474
Current liabilities:
Current maturities of long-term debt	2,072	2,040
Accounts payable	13,173	10,423
Accrued salaries, wages and commissions	3,497	3,113
Other accrued liabilities	3,552	3,739
Total current liabilities	22,294	19,315
Long-term debt, less current maturities	11,205	9,321
Other postretirement benefit obligations	433	455
Accrued pension liabilities	776	772
Other long-term liabilities	3,200	3,172
Total liabilities	37,908	33,035
Commitments and contingencies (note 14)
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 7,037 and 6,900 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	7,037	6,900
Additional paid-in capital	22,489	21,581
Accumulated deficit	(3,281)	(6,056)
Accumulated other comprehensive loss	(899)	(733)
Total shareholders' equity	25,346	21,692
Non-controlling interest	(279)	(253)
Total equity	25,067	21,439
Total liabilities and equity	$ 62,975	$ 54,474

Consolidated Condensed Balance3

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Consolidated Condensed Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 577	$ 332
Common stock, par value	$ 1	$ 1
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	7,037,000	6,900,000
Common stock, shares outstanding	7,037,000	6,900,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Consolidated Condensed Statements of Operations [Abstract]
Sales, net	$ 30,160	$ 22,524	$ 55,523	$ 43,739
Cost of sales	20,171	15,885	37,122	31,266
Gross profit	9,989	6,639	18,401	12,473
Operating expenses:
Sales and marketing	2,881	2,204	5,721	4,515
General and administrative	3,108	2,705	6,169	5,263
Research and development	1,316	1,112	2,475	2,265
Total operating expenses	7,305	6,021	14,365	12,043
Operating income	2,684	618	4,036	430
Interest expense	(211)	(189)	(405)	(371)
Other income (expense)	(196)	(47)	(401)	9
Income from continuing operations before income taxes and discontinued operations	2,277	382	3,230	68
Income tax expense	269	54	455	118
Income (loss) from continuing operations before discontinued operations	2,008	328	2,775	(50)
Loss on sale of discontinued operations (Note 3)				(164)
Loss from discontinued operations (Note 3)		(15)		(128)
Net income (loss)	2,008	313	2,775	(342)
Less: Loss allocated to non-controlling interest		(355)		(740)
Net income attributable to IntriCon shareholders	$ 2,008	$ 668	$ 2,775	$ 398
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$ 0.29	$ 0.10	$ 0.40	$ 0.10
Discontinued operations				(0.04)
Net income (loss) per share:	0.29	0.10	0.40	0.06
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations	0.25	0.10	0.35	0.10
Discontinued operations				(0.04)
Net income (loss) per share:	$ 0.25	$ 0.09	$ 0.35	$ 0.06
Average shares outstanding:
Basic	6,991	6,845	6,930	6,828
Diluted	8,118	7,187	8,021	6,828

Consolidated Condensed Stateme5

Consolidated Condensed Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Consolidated Condensed Statements of Comprehensive Income [Abstract]
Net income (loss)	$ 2,008	$ 313	$ 2,775	$ (342)
Interest rate swap, net of taxes of $0	(1)	3	3	15
Pension and postretirement obligations, net of taxes of $0	5	5	10	10
Foreign currency translation adjustment, net of taxes of $0	(257)	80	(179)	125
Comprehensive income (loss)	$ 1,755	$ 401	$ 2,609	$ (192)

Consolidated Condensed Stateme6

Consolidated Condensed Statements Of Comprehensive Income (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Consolidated Condensed Statements of Comprehensive Income [Abstract]
Interest rate swap, tax	$ 0	$ 0	$ 0	$ 0
Pension and postretirement obligations, tax	0	0	0	0
Foreign currency translation adjustment, tax	$ 0	$ 0	$ 0	$ 0

Consolidated Condensed Stateme7

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income (loss)	$ 2,775	$ (342)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,432	1,105
Stock-based compensation	667	425
Loss on sale of discontinued operations		164
Change in allowance for doubtful accounts	245	20
Equity in loss of partnerships	222	24
Changes in operating assets and liabilities:
Accounts receivable	(1,255)	(1,043)
Inventories	(1,918)	(1,196)
Contract assets	(3,053)	(682)
Other assets	(377)	(458)
Accounts payable	1,480	2,113
Accrued expenses	(389)	432
Other liabilities	428	(37)
Net cash provided by operating activities	257	525
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,608)	(618)
Investment in partnerships	(539)	(100)
Net cash used in investing activities	(2,147)	(718)
Cash flows from financing activities:
Proceeds from long-term debt	10,833	7,481
Repayments of long-term debt	(9,055)	(7,843)
Proceeds from employee stock purchases and exercise of stock options	378	129
Change in restricted cash	(11)	(56)
Net cash provided by (used in) financing activities	2,145	(289)
Effect of exchange rate changes on cash	(89)	178
Net increase (decrease) in cash	166	(304)
Cash, beginning of period	373	667
Cash, end of period	539	$ 363
Noncash investing and financing:
Investment in partnerships through liability incurred	187
Acquisition of property, plant and equipment in accounts payable	$ 1,265

General

General	6 Months Ended
	Jun. 30, 2018
General [Abstract]
General	1. General  In the opinion of management, the accompanying consolidated condensed financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly IntriCon Corporation's (“IntriCon” or the “Company”) consolidated financial position as of June 30, 201 8 and December 31, 2017 , the consolidated results of its operations for the three and six months ended June 30, 201 8 and 20 17 and cash flows for t he six months ended June 30, 2018 and 2017 . Results of operations for the interim periods are not necessarily indicative of the results of operations expected for the full year or any other interim period.  In December 2016, the Company’s board of directors approved plans to discontinue its cardiac diagnostic monitoring business. The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC. For all periods presented, the Company classified this business as discontinued operations, and, accordingly, has reclassified historical financial data presented herein. The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.  In December 2017, the Company acquired the remaining 80 -percent stake in Hearing Help Express, Inc. (referred to as “Hearing Help Express” or “HHE”), a direct-to-consumer mail order hearing aid provider, for $650 in cash, repayment of $1,833 in debt to HHE’s 80% holder and an earn-out. The results of HHE have been consolidated into the Company’s financial statements since October 31, 2016. Prior to the acquisition of 100% ownership in December 2017, the Company allocated income and losses to the noncontrolling interest based on ownership percentage. In February 2018, the Company closed on an additional 33% ownership interest in Soundperience, bringing its total ownership to 49% and its total investment to 1,500 Euros consisting of an equity investment and license agreement. Soundperience has designed self-fitting hearing aid technology. The Company does not anticipate the Soundperience business will have a notable financial impact on operating results, but rather will provide the Company with exclusive access in the United States to critical software technology. Soundperience’s self-fitting hearing aid technology is being used in the German market today, most notably through Signison, the Company’s joint venture with the majority owner of Soundperience. Soundperience and Signison are accounted for in the Company’s financial statements using the equity method.  The Company has evaluated subsequent events occurring after the date of the consolidated financial statements for events requiring recording or disclosure in the consolidated financial statements.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Retirement Benefits – Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This guidance requires entities to present the service cost component of net periodic pension cost and net periodic postretirement benefit cost in the income statement line items where they report compensation cost. Entities will present all other components of net benefit cost outside operating income, if this subtotal is presented. The rules related to the timing of when costs are recognized or how they are measured have not changed. This amendment only impacts where those costs are reflected within the income statement. In addition, only the service cost component will be eligible for capitalization in inventory and other assets. This guidance became effective January 1, 2018. The adoption of this new standard did not have a material impact on the Company’s consolidated financial statements.  In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force (the “Task Force”). The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. This update is effective for years beginning after December 31, 2018. The Company has restricted cash balances and anticipates that the adoption of this new standard will change the cash amounts and financing activities on its statement of cash flows on its consolidated financial statements. In February 2016, the FASB issued its final standard on accounting for leases. This standard, issued as ASU 2016-02, requires that an entity that is a lessee to recognize lease assets and lease liabilities on the balance sheet for all leases and disclose key information about leasing arrangements. This update is effective for financial statement periods beginning after December 15, 2018, with earlier application permitted. The Company has not yet determined the impact of this pronouncement on its consolidated financial statements and related disclosures, but anticipates it will be required to record additional lease liabilities and corresponding rights to use assets.  

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2018
Discontinued Operations [Abstract]
Discontinued Operations	3. Discontinued Operations    The following table shows the results of the cardiac diagnostic monitoring discontinued operations:     Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017  Sales, net $ - $ - $ - $ 140  Operating costs and expenses - (15) - (268)  Net loss from discontinued operations - (15) - (128)   The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC for a future revenue earn-out that was valued by the Company at $0 . The Company has not earned any earn-out revenue through June 30, 2018. The Company recorded a loss on the sale of $164 . The net loss was computed as follows:     Accounts receivable, net $ 179  Accrued liabilities (15)  Net assets sold $ 164  Fair value of consideration received -  Loss on sale of discontinued operations, net of income taxes $ 164 

Changes In Accounting Policies

Changes In Accounting Policies	6 Months Ended
	Jun. 30, 2018
Changes In Accounting Policies [Abstract]
Changes In Accounting Policies	4. Changes in Accounting Policies  The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. In May 2014, the FASB issued ASU 2014-09 “Topic 606. Revenue from Contracts with Customers” (Topic 606). Topic 606 supersedes the revenue recognition requirements previously set forth in the Accounting Standards Codification (ASC) Topic 605 “Revenue Recognition,” and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted Topic 606 with a date of initial application of January 1, 2018. The Company applied Topic 606 retrospectively using the practical expedient in ASC 606-10-65-1(f)(3). The Company notes that all previously reported historical amounts are adjusted for the impact of ASC 606.  Changes to the Company’s significant accounting policies as a result of adopting Topic 606 are discussed below: Revenue recognition - Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including noncash consideration, consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under “Performance obligations”. Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct, i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement. When an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated stand-alone selling price. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under ASC 340-40 or other applicable guidance are met. Cost of revenues consist primarily of direct labor, manufacturing overhead, materials and components. The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The Company includes shipping and handling fees in sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the Consolidated Balance Sheet as further described below under “Receivables, net”, “Contract assets” and “Contract liabilities”. When more than one party is involved in providing goods or services to a customer, an entity determines whether it is a principal or an agent in these transactions by evaluating the nature of its promise to the customer. An entity is a principal and therefore records revenue on a gross basis if it controls a promised good or service before transferring that good or service to the customer. An entity is an agent and records as revenue the net amount it retains for its agency services if its role is to arrange for another entity to provide the goods or services. Performance obligations - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s various performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below: Medical market - Customer orders from the medical market consist of a specified number of assembled and customized parts that the customer further integrates into their production process to produce market ready products. Customer orders do not include additional follow-on goods or services. With the exception of prompt payment discounts, the transaction price for medical market products is the invoiced amount, as variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price are not present. All of the Company’s products manufactured for the medical market are designed to each customer’s specifications, do not have an alternative use and cannot be sold or redirected by the Company to others. The Company has an enforceable right to payment for any finished or in-process units, including a reasonable margin, if the customer terminates the contract for reasons other than the Company’s failure to perform as promised. Control of these units is deemed to transfer to the customer over time during the manufacturing process, using the same measure of progress toward satisfying the promise to deliver the units to the customer. Each order is for a series of distinct units that comprise a single performance obligation. Consequently, the transaction price is recognized as revenue over time based on actual costs incurred in the manufacturing process to date relative to total expected costs to produce all ordered units.  Medical market products are invoiced when shipped and paid within normal commercial terms. The Company records a contract asset for revenue recognized over time in the production process for customized products that have not been shipped or invoiced to the customer. Hearing health market - Customer orders from the hearing health market consist of hearing aid devices and related accessories. Each unit of product delivered under a customer order represents a distinct and separate performance obligation as the customer can benefit from each unit on its own or with other resources that are readily available to the customer and each unit of product is separately identifiable from other products in the arrangement. With the exception of prompt payment discounts, the transaction price for the hearing health markets products is the invoiced amount, as variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price are not present. Nearly all of the Company’s products manufactured for the hearing health market could be reworked without significant cost and sold to another customer in the event of the customer’s termination of an order before delivery, and therefore have an alternative use to the Company. Generally, revenue is recognized upon the transfer of control of the products which is based on shipment terms; however, in certain cases the amount of shipment is adjusted for expected future returns and related consideration received. Professional audio market - The Company sells body-worn audio devices with application in the aviation, fire, law enforcement, safety and military markets as well as for performers and production staff in the music and stage performance markets. Each unit on a customer’s purchase order represents a distinct and separate performance obligation as the customer can benefit from each unit on its own or with other resources that are readily available to the customer and each unit is separately identifiable from the others because one does not significantly affect, modify or customize another. Variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting the transaction price are not present. Invoiced amounts are deemed to approximate standalone selling price, such that a relative standalone selling price allocation between performance obligations is not required. The products manufactured for the professional audio market could be reworked without significant cost and sold to another customer in the event of the customer’s termination of an order before delivery and therefore have an alternative use to the Company. Transfer of control of the goods, and revenue recognition, occurs at the point in time of shipment or delivery of the products to the customer depending on the applicable shipping terms. Professional audio market products are billed when shipped and paid within normal commercial terms. Hearing health direct-to-consumer (DTC) market - The hearing health DTC business distributes hearing aids and related accessories to the end consumer and is the Company’s only business market that generates revenue from sales to the end consumer. The Company also sells a limited number of service plans for the hearing aids. Each product or service is a distinct performance obligation as each is independently useful either on its own or together with other products procured from the Company or other vendors and each product or service is separately identifiable from the others because one does not significantly affect, modify or customize another. Invoiced amounts are deemed to approximate standalone selling price, therefore a relative standalone selling price allocation between performance obligations is not required. The hearing health DTC business offers a 60 -day trial period to the end consumer for hearing aids, during which customers can return the hearing aids for a full refund or exchange for a different hearing aid. The Company invoices for the hearing aids and recognizes revenue only after completion of the 60-day trial period, when the customer’s commitment to the arrangement is deemed to exist and an enforceable right to payment is established. The transaction price for hearing aid accessories and service plans is the invoiced amount, as variable consideration in the form of refunds, credits, rebates, price concessions, pricing incentives or other items impacting transaction price are not present. Hearing aid accessories are billed and revenue is recognized upon shipment to the customer. Invoices are paid within normal commercial terms. Annual service plans are billed along with the hearing aid at the end of the 60-day trial period or upon renewal of the service plan, and paid within normal commercial terms. As the customer consumes the benefits of the service plan relatively evenly over the plan term, revenue for service plans is recognized on a straight-line basis commencing at the end of the trial period.  Receivables, net – Excluding the hearing health direct-to-consumer market, amounts recorded in receivables, net, on the consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience and the age of outstanding receivables. For the hearing health direct-to-consumer market, receivables, net, include amounts billed and currently due from customers and amounts to become due from customers on trial programs. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not be collected. Contract Assets - Contract assets primarily include unbilled amounts recognized as revenue for customized products manufactured for the medical market. The customized goods have no alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. The Company begins revenue recognition when these goods enter the manufacturing process and continues based on a measure of progress toward completion using a cost-to-cost input method that considers labor and overhead costs incurred and materials used to date in the manufacturing process relative to total expected production costs. Given the relatively short duration of the production process, contract assets are classified as current. Contract assets are reclassified to accounts receivable upon shipment of and invoicing for the products, at which point the right to consideration becomes unconditional. Sales Commissions - Sales commissions paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. The Company has elected to apply the practical expedient provided by ASC 340-40-25-4 and recognize the incremental costs of obtaining contracts as an expense when incurred, as the amortization period of the assets that would have otherwise been recognized is one year or less. These costs are included in sales and marketing expenses on the consolidated statements of operations. Product Warranty - The Company offers warranties on various products and services. These warranties are assurance type warranties not sold on a standalone basis, and therefore are not considered distinct performance obligations. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. 

Significant Changes Due To Topi

Significant Changes Due To Topic 606	6 Months Ended
	Jun. 30, 2018
Significant Changes Due To Topic 606 [Abstract]
Significant Changes Due To Topic 606	5 . S ignificant Changes Due to Topic 606  Sales of Customized Medical Products - The primary factor impacting the timing of the Company’s reported net income (loss) in the financial statements as a result of the adoption of Topic 606 is the acceleration of revenue and associated cost of sales recognized from the sale of customized medical products. For sales of these products, the Company previously recognized revenue at a point in time when the products were completed and shipped to the customer. Under Topic 606, if control of the products is transferred to the customer over the manufacturing process and the criteria for over time revenue recognition are otherwise met, revenue is recognized as products are manufactured utilizing an appropriate measure of progress toward satisfaction of the performance obligation. The Company’s contracts with customers for the production of customized medical products meet the criteria for over time revenue recognition; therefore, the Company utilizes an input method based on actual costs incurred in the manufacturing process to date relative to total expected production costs as a measure of progress toward transfer of control of the products to the customer and recognizes revenue on that basis. Amounts recognized as revenue but not yet shipped or billed to the customer are recorded as contract assets. See Note 4 for further discussion. Principal vs. Agent Role in Sales under Supply Arrangement - The Company has determined that the nature of its promise to a third-party supplier is a performance obligation to provide the integrated hearing aid products to its customers and that the associated sales contracts meet the control criteria necessary to qualify the Company as the principal in the transactions. As a result, gross reporting of revenues for sales under the supply arrangement is appropriate under Topic 606 and the profit sharing amount due to the third party is reported as cost of sales. Impacts on financial statements Previously reported amounts for sales, cost of sales, contract assets and contract liabilities have been retrospectively adjusted to provide amounts comparable to the reporting under Topic 606. The following tables summarize the effects of adopting this accounting standard on the Company’s unaudited Consolidated Financial Statements.  Consolidated Statement of Operations:     Three Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Three Months Ended June 30, 2017, as adjusted Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Sales, net $ 21,961 $ 563 $ 22,524 $ 42,049 $ 1,690 $ 43,739  Cost of sales 15,380 505 15,885 29,792 1,474 31,266  Gross profit 6,581 58 6,639 12,257 216 12,473   Operating expenses:  Sales and marketing 2,204 - 2,204 4,515 - 4,515  General and administrative 2,705 - 2,705 5,263 - 5,263  Research and development 1,112 - 1,112 2,265 - 2,265  Total operating expenses 6,021 - 6,021 12,043 - 12,043  Operating income (loss) 560 58 618 214 216 430   Interest expense (189) - (189) (371) - (371)  Other income (47) - (47) 9 - 9  Income (loss) from continuing operations before income taxes and discontinued operations 324 58 382 (148) 216 68  Income tax expense 54 - 54 118 - 118  Income (loss) from continuing operations before discontinued operations 270 58 328 (266) 216 (50)  Loss on sale of discontinued operations (Note 3) - - - (164) - (164)  Loss from discontinued operations (Note 3) (15) - (15) (128) - (128)  Net income (loss) 255 58 313 (558) 216 (342)  Less: Loss allocated to non-controlling interest (355) - (355) (740) - (740)  Net income (loss) attributable to IntriCon shareholders $ 610 $ 58 $ 668 $ 182 $ 216 $ 398   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.09 $ 0.01 $ 0.10 $ 0.07 $ 0.03 $ 0.10  Discontinued operations - - $ - (0.04) - (0.04)  Net income (loss) per share: $ 0.09 $ 0.01 $ 0.10 $ 0.03 $ 0.03 $ 0.06   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.09 $ 0.01 $ 0.10 $ 0.07 $ 0.03 $ 0.10  Discontinued operations - - - (0.04) - (0.04)  Net income (loss) per share: $ 0.08 $ 0.01 $ 0.09 $ 0.03 $ 0.03 $ 0.06   Average shares outstanding:  Basic 6,845 6,845 6,845 6,828 6,828 6,828  Diluted 7,187 7,187 7,187 6,828 6,828 6,828   Consolidated Statement of Comprehensive Income (Loss):     Three Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Three Months Ended June 30, 2017, as adjusted   Net income $ 255 $ 58 $ 313   Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Net income (loss) $ (558) $ 216 $ (342)  Consolidated Statement of Cash Flows:    Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Net income (loss) $ (558) $ 216 $ (342)  Inventories (1,662) 466 (1,196)  Contract assets - (682) (682)  Prior Year Consolidated Balance Sheet:     December 31, 2017, as reported Effect of Adoption of ASC 606 December 31, 2017, as adjusted   Inventories $ 15,397 $ (1,689) $ 13,708  Contract assets - 2,979 2,979  Other accrued liabilities 3,224 515 3,739  Accumulated deficit (6,831) 775 (6,056)  In addition, the cumulative impact to the Company’s retained earnings at January 1, 2017 was a decrease to the accumulated deficit of $518 . Transaction price allocated to remaining performance obligations - The Company’s remaining performance obligations as of June 30, 2018 primarily include uncompleted production of customized products for which control transfers to the customer over time, certain uncompleted product sales for orders received and future obligations under service plan arrangements recognized over time. The Company has elected to apply the practical expedient provided in ASC 606-10-50-14 and not disclose information about the amount of transaction price allocated to these remaining performance obligations as they all have original expected durations of one year or less. The following table provides information about receivables, contracts assets, and contract liabilities from contracts with customers.     June 30, 2018 December 31, 2017, as adjusted   Receivables, included in accounts receivable, less allowance for doubtful account $ 10,067 $ 9,052  Contract assets 6,032 2,979  Contract liabilities, included in other current liabilities 402 312  Significant changes in contract assets and contract liabilities during the period are as follows:    For the six months ended June 30, 2018  Contract assets increase (decrease) Contract liabilities (increase) decrease   Reclassification of beginning contract liabilities to revenue, as a result of performance obligations satisfied $ - $ 312  Cash received in advance and not recognized as revenue - (402)  Reclassification of beginning contract assets to accounts receivable, as a result of right to consideration becoming unconditional - -  Contract assets recognized, net of reclassification to accounts receivable 3,053  Cumulative catch-up from a change in the timeframe for recognition of revenue arising from a contract liability - -  Increase as a result of cumulative catch-up adjustment arising from changes in the estimate of costs incurred relative to total amounts projected, excluding amounts transferred to receivables during the period. -  Net Change $ 3,053 $ (90) 

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2018
Segment Reporting, Geographic Information [Abstract]
Segment Reporting	6 . Segment Reporting  The Company currently operates in two reportable segments: body-worn devices and hearing health direct-to-consumer. The nature of distribution and services has been deemed separately identifiable. Therefore, segment reporting has been applied. Income (loss) from operations is total revenues less cost of sales and operating expenses. Identifiable assets by industry segment include assets directly identifiable with those operations. The accounting policies applied to determine segment information are the same as those described in the summary of significant accounting policies described in and incorporated by reference from “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 1 to the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. The Company evaluates the performance of each segment based on income and loss from continuing operations before income taxes. The following table summarizes data by industry segment:     At and for the Three Months Ended June 30, 2018 Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 28,108 $ 2,052 $ 30,160  Income (loss) from continuing operations 2,509 (501) 2,008  Identifiable assets (excluding goodwill) 46,173 5,994 52,167  Goodwill 9,551 1,257 10,808  Depreciation and amortization 727 51 778  Capital expenditures 1,067 56 1,123   At and for the Six Months Ended June 30, 2018 Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 51,680 $ 3,843 $ 55,523  Income (loss) from continuing operations 3,729 (954) 2,775  Identifiable assets (excluding goodwill) 46,173 5,994 52,167  Goodwill 9,551 1,257 10,808  Depreciation and amortization 1,332 100 1,432  Capital expenditures 1,542 66 1,608   At and for the Three Months Ended June 30, 2017 (as adjusted) Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 21,115 $ 1,409 $ 22,524  Income (loss) from continuing operations 753 (425) 328  Identifiable assets (excluding goodwill) 31,613 4,467 36,080  Goodwill 9,551 1,004 10,555  Depreciation and amortization 499 44 543  Capital expenditures 273 72 345   At and for the Six Months Ended June 30, 2017 (as adjusted) Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 40,914 $ 2,825 $ 43,739  Income (loss) from continuing operations 828 (878) (50)  Identifiable assets (excluding goodwill) 31,613 4,467 36,080  Goodwill 9,551 1,004 10,555  Depreciation and amortization 994 111 1,105  Capital expenditures 486 132 618 

Geographic Information

Geographic Information	6 Months Ended
	Jun. 30, 2018
Segment Reporting, Geographic Information [Abstract]
Geographic Information	7 . Geographic Information  The geographical distribution of long-lived assets to geographical areas consisted of the following at:     June 30, December 31,  2018 2017  United States $ 7,513 $ 5,407  Singapore 1,143 1,254  Other – primarily United Kingdom and Indonesia 497 514  Consolidated $ 9,153 $ 7,175    Long-lived assets consist of property and equipment. Excluded from long-lived assets are investments in partnerships, patents, license agreements and goodwill. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets.  The geographical distribution of net sales to geographical areas for the three and six months ended June 30, 201 8 and 201 7 were as follows:       Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 (as adjusted) June 30, 2018 June 30, 2017 (as adjusted)  United States $ 25,255 $ 18,239 $ 45,714 $ 34,889  Europe 1,884 2,307 4,162 4,785  Asia 2,699 1,891 5,167 3,801  All other countries 322 87 480 264  Consolidated $ 30,160 $ 22,524 $ 55,523 $ 43,739  Geographic net sales are allocated based on the location of the customer. For the three and six months ended June 30, 2018, one customer accounted for 57% and 56% , respectively , of the Company’s consolidated net sales. For the three and six mo nths ended June 30, 2017, one customer accounted for 49% and 47% , respectively, of the Company’s consolidated net sales. At June 30, 201 8 , two customers combined accounted f or 35% of the Company’s consolidated accounts receivable. At December 31, 2017, two customers combined accounted for 32% of the Company’s consolidated accounts receivable. At June 3 0, 2018, one custome r accounted for 77% of the Company’s consolidated contract assets. At December 31, 2017, one customer accounted for 62% of the Company’s consolidated contract assets.

Investment In Partnerships

Investment In Partnerships	6 Months Ended
	Jun. 30, 2018
Investment In Partnerships [Abstract]
Investment In Partnerships	8 . In vestment in Partnerships  Investment in partnerships consisted of the following:     June 30, December 31,  2018 2017  Investment in Soundperience $ 1,091 $ 842  Investment in Signison 539 498  Other 235 276  Total $ 1,865 $ 1,616   As of March 31, 2018, the Company held a 49% ownership interest in Soundperience. In February 2018, the Company acquired an additional 33% stake in Soundperience. Soundperience is accounted for in the Company’s financial statements using the equity method as of June 3 0 , 2018 . The Company’s investment in Soundperience exceeded the underlying interest in net equity of the Company. As a result, the Company assigned the excess investment to related intangible assets and includes the amortization of those intangibles within the equity in the income (losses) of Soundperience, which are included in other income (expenses) in the consolidated statements of operations. Soundperience’s income (loss) in earnings is immaterial for the periods presented. The Company has a 50% stake in Signison as of June 3 0 , 2018. Signison is accounted for in the Company’s financial statements using the equity method.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2018
Inventories [Abstract]
Inventories	9 . Inventories Inventories consisted of the following at:     Raw materials Work-in process Finished products and components Total  June 30, 2018  Domestic $ 8,148 $ 2,080 $ 1,216 $ 11,444  Foreign 2,231 1,039 930 4,200  Total $ 10,379 $ 3,119 $ 2,146 $ 15,644   December 31, 2017 (as adjusted)  Domestic $ 6,924 $ 1,791 $ 1,366 $ 10,081  Foreign 2,258 514 855 3,627  Total $ 9,182 $ 2,305 $ 2,221 $ 13,708 

Short And Long-Term Debt

Short And Long-Term Debt	6 Months Ended
	Jun. 30, 2018
Short And Long-Term Debt [Abstract]
Short And Long-Term Debt	10 . Short and Long-Term Debt  Short and long-term debt is summarized as follows:     June 30, December 31,  2018 2017   Domestic Asset-Based Revolving Credit Facility $ 6,394 $ 4,000  Capital expenditure loan facility - -  Foreign Overdraft and Letter of Credit Facility 1,241 1,250  Domestic Term-Loan 5,750 6,250  Unamortized Finance Costs (108) (139)  Total Debt 13,277 11,361  Less: Current maturities (2,072) (2,040)  Total Long-Term Debt $ 11,205 $ 9,321   Domestic Credit Facilities The Company and its domestic subsidiaries are parties to a credit facility with CIBC Bank USA (formerly known as The PrivateBank and Trust Company). The credit facility, as amended through June 3 0 , 2018, provides for:   ▪ a $9,000 revolving credit facility, with a $200 sub facility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of the Company’s eligible trade receivables and eligible inventory, and eligible equipment less a reserve;   ▪ a $2,500 capital expenditure loan facility under which the Company at its election, can draw up to $2,500 for qualifying capital expenditures over the period ending December 15, 2018, with monthly amortization commencing after such time; and  ▪ a term loan in the original amount of $6,500 .  The credit facility matures on December 15, 2022. All of the borrowings under this agreement have been characterized as either a current or long-term liability on our balance sheet in accordance with the repayment terms described more fully below. Weighted average interest on the revolving credit facility w as 5.25% for the six months ended June 30, 2018 and 5.11% for the year ended December 31, 2017. The outstanding principal balance of the term loan, as amended, is payable in quarterly installments of $250 . Any remaining principal and accrued interest is payable on December 15, 2022. IntriCon is also required to use 100% of the net cash proceeds of certain asset sales (excluding inventory and certain other dispositions), sale of capital securities or issuance of debt to pay down the term loan.  The Company was in compliance with the financial covenants under the facility as of June 30, 2018.  The credit facility was amended on July 23, 2018. See Note 17.  Foreign Credit Facility In addition to its domestic credit facilities, the Company’s wholly-owned subsidiary, IntriCon, PTE LTD., entered into an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for an asset-based line of credit. Borrowings bear interest at a rate of .75% to 2.5% over the lender’s prevailing prime lending rate. Weighted average interest on the international credit facilities was 4.30% and 3.87% for the six months ended June 30, 201 8 and the year ended December 31, 2017.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Taxes [Abstract]
Income taxes	11 . Income Taxes  Income tax expense for the three and six months ended June 30, 201 8 was $ 269 and $455 , respectively, compared to $ 54 and $ 118, respectively, for the same per iods in 2017. The expense was primarily due to domestic state income tax along with some foreign taxes for those periods in 2018 and 2017 . The Company has net operating loss carryforwards for U.S. federal income tax purposes and, consequently, minimal federal benefit or expense from the domestic operations was recognized as the deferred tax asset has a full valuation allowance.  The following was the income (loss) before income taxes for each jurisdiction in which the Company has operations for the three and six months ended June 30, 201 8 and 201 7 .      Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017  United States $ 2,450 $ 486 $ 3,299 $ 257  Singapore 98 16 346 (77)  Indonesia 21 18 42 34  United Kingdom (334) (286) (570) (411)  Germany 42 148 113 265  Income (loss) before income taxes $ 2,277 $ 382 $ 3,230 $ 68 

Shareholders' Equity And Stock-

Shareholders' Equity And Stock-Based Compensation	6 Months Ended
	Jun. 30, 2018
Shareholders' Equity And Stock-Based Compensation [Abstract]
Shareholders' Equity And Stock-Based Compensation	12. Shareholders’ Equity and Stock-based Compensation  The Company has a 2006 Equity Incentive Plan and a 2015 Equity Incentive Plan. The 2015 Equity Incentive Plan replaced the 2006 Equity Incentive Plan and new grants may not be made under the 2006 Plan. Under the 2015 Equity Incentive Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”) and other equity-based awards. Under all awards, the terms are fixed on the grant date. The Company granted 11 and 98 RSUs for the three and six months ended June 30, 2018. The closing price of the Company’s common stock on the date of grant was $23.50 and $20.61 , respectively, for the RSUs granted in the first quarter and second quarter of 2018 . The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units. The Company also has granted stock options under the plans. Options granted under the plans generally vest over three years and have a maximum term of 10 years.  Stock option activity during the six months ended June 30, 2018 was as follows:       Outstanding Awards Weighted-average Aggregate  Stock Options RSUs Total Exercise Price (a) Intrinsic Value   Outstanding at December 31, 2017 1,453 - 1,453 $ 5.95  Forfeited, cancelled or expired (18) - (18) 7.93  Granted - 98 98 -  Exercised (186) - (186) 6.23   Outstanding at June 30, 2018 1,249 98 1,347 $ 5.52 $ 46,832   Exercisable at June 30, 2018 964 - 964 $ 5.58 $ 33,479   Available for future grant at December 31, 2017 251   Available for future grant at June 30, 2018 215   (a) The weighted average exercise price calculation does not include outstanding RSUs.  The number of shares available for future grants at June 30, 2018 does not include a total of up to 763 shares subject to options outstanding under the 2006 Equity Incentive Plan which will become available for grant under the 2015 Equity Incentive Plan in the event of the expiration, cancellation or surrender of such options.  The Company recorded $333 and $667 of non-cash stock compensation expense for the three and six months ended June 30, 2018, respectively. The Company recorded $207 and $425 of non-cash stoc k compensation expense for the three and six months ended June 30, 2017, respectively. As of June 30, 2018, there was $2,639 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 2.28 years.  The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through June 30, 2018, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 1 and 4 shares purchased under the plan for the three and six months ended June 30 , 2018, respectively, and a total of 3 and 7 shares purchased for the three and six months ended June 30, 2017, respectively.

Income (Loss) Per Share

Income (Loss) Per Share	6 Months Ended
	Jun. 30, 2018
Income (Loss) Per Share [Abstract]
Income (Loss) Per Share	13 . Income (Loss) Per Share  The following table presents a reconciliation between basic and diluted earnings per share:     Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 (as adjusted) June 30, 2018 June 30, 2017 (as adjusted)  Numerator:  Income (loss) from continuing operations before discontinued operations $ 2,008 $ 328 $ 2,775 $ (50)  Loss on sale of discontinued operations - - - (164)  Loss from discontinued operations, net of income taxes - (15) - (128)   Net income (loss) 2,008 313 2,775 (342)   Less: loss allocated to non-controlling interest - (355) - (740)   Net income (loss) attributable to shareholders $ 2,008 $ 668 $ 2,775 $ 398   Denominator:  Basic – weighted shares outstanding 6,991 6,845 6,930 6,828  Weighted shares assumed upon exercise of stock options 1,127 342 1,091 -  Diluted – weighted shares outstanding 8,118 7,187 8,021 6,828   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.29 $ 0.10 $ 0.40 $ 0.10  Discontinued operations - - - (0.04)  Net income (loss) per share: $ 0.29 $ 0.10 $ 0.40 $ 0.06   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.25 $ 0.10 $ 0.35 0.10  Discontinued operations - - - (0.04)  Net income (loss) per share: $ 0.25 $ 0.09 $ 0.35 $ 0.06     The dilutive impact summarized above relates to the periods when the average market price of Company stock exceeded the exercise price of the potentially dilutive option securities granted. Earnings per common share was based on the weighted average number of common shares outstanding during the periods when computing the basic earnings per share. When dilutive, stock options are included as equivalents using the treasury stock method when computing the diluted earnings per share. Individual components of basic and diluted income (loss) per share may not sum to the total income (loss) per share due to rounding.  Excluded from the computation of diluted earnings per share for the six months ended June 30, 201 7 were outstanding in the money options to purchase approximately 314 common shares, respectively, because the effect would have been anti-dilutive due to the Company’s net loss in the period. No options were excluded from the dilutive calculation for the three and six months ended June 30, 2018.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2018
Legal Proceedings [Abstract]
Legal Proceedings	14 . Legal Proceedings  The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or advised the Company that they need to investigate further. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, many of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company's consolidated financial position or results of operations.  The Company’s former French subsidiary, Selas SAS, filed for insolvency in France. The Company may be subject to additional litigation or liabilities as a result of the French insolvency proceeding, including liabilities under guarantees aggregating approximately $456 .  The Company is also involved in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect our consolidated financial position, liquidity or results of operations. 

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2018
Related-Party Transactions [Abstract]
Related-Party Transactions	15 . Related-Party Transactions  The Company uses the law firm of Blank Rome LLP for legal services. A partner of that firm is the son-in-law of the Chairman of the Company’s Board of Directors. For the three and six months ended June 30, 201 8 , the Company paid that firm approximately $72 and $175 , respectively , for legal services and costs. For the three and six months ended June 30 , 2017 , the Company paid that firm approximately $27 and $66 , respectively, for legal services and costs. The Chairman of our Board of Directors is considered independent under applicable Nasdaq and Securities and Exchange Commission rules because (i) no payments were made to the Chairman or the partner directly in exchange for the services provided by the law firm and (ii) the amounts paid to the law firm did not exceed the thresholds contained in the Nasdaq standards. Furthermore, the aforementioned partner does not provide any legal services to the Company and is not involved in billing matters.

Revenue By Market

Revenue By Market	6 Months Ended
	Jun. 30, 2018
Revenue By Market [Abstract]
Revenue By Market	16 . Revenue by Market  The following tables set forth, for the periods indicated, net revenue by market:      Timing of revenue recognition for the three months ended June 30, 2018:  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 20,198 $ 20,198  Hearing Health 6,390 - 6,390  Professional Audio Communications 1,520 - 1,520  Hearing Health DTEC Segment:  Hearing Health DTEC 2,052 - 2,052  Total Revenue $ 9,962 $ 20,198 $ 30,160   Timing of revenue recognition for the six months ended June 30, 2018:  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 36,131 $ 36,131  Hearing Health 12,200 - 12,200  Professional Audio Communications 3,349 - 3,349  Hearing Health DTEC Segment:  Hearing Health DTEC 3,843 - 3,843  Total Revenue $ 19,392 $ 36,131 $ 55,523   Timing of revenue recognition for the three months ended June 30, 2017 (as adjusted):   Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 13,572 $ 13,572  Hearing Health 6,035 - 6,035  Professional Audio Communications 1,508 - 1,508  Hearing Health DTEC Segment:  Hearing Health DTEC 1,409 - 1,409  Total Revenue $ 8,952 $ 13,572 $ 22,524   Timing of revenue recognition for the six months ended June 30, 2017 (as adjusted):  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 25,752 $ 25,752  Hearing Health 12,272 - 12,272  Professional Audio Communications 2,890 - 2,890  Hearing Health DTEC Segment:  Hearing Health DTEC 2,825 - 2,825  Total Revenue $ 17,987 $ 25,752 $ 43,739 

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	  17 . Subsequent Events  On July 23, 2018, the Company and its domestic subsidiaries entered into the Twelfth Amendment to the Loan and Security Agreement with CIBC Bank USA. The amendment, among other things:  • Increased IntriCon’s capex loan facility capacity to $10 million from its then current capacity of $2.5 million. The C ompany at its election, can draw up to $10 million on the loan for qualifying cap ital expenditures through June 30, 2019 , with monthly amortization commencing after such time; • Increased IntriCon’s revolving credit facility capacity to $11.0 million from its then current capacity of $9.0 million; • Raised the inventory cap on the borrowing base from $4.5 million to $5.0 million. Under the revolving credit facility as amended, the availability of funds depends on a borrowing base composed of stated percentages of the Company’s eligible trade receivables and inventory, less a reserve;, • Increased the annual capital expenditures allowed under the facilities from its current limit of $5.5 million to $12.0 million for the fiscal year ending December 31, 2018 and $5.5 million in the aggregate in the fiscal year ending December 31, 2019 or in any fiscal year thereafter; and • Lowered applicable interest rates by 0.25% .  

New Accounting Pronouncements (

New Accounting Pronouncements (Policy)	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements [Abstract]
New Accounting Pronouncements	In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Retirement Benefits – Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This guidance requires entities to present the service cost component of net periodic pension cost and net periodic postretirement benefit cost in the income statement line items where they report compensation cost. Entities will present all other components of net benefit cost outside operating income, if this subtotal is presented. The rules related to the timing of when costs are recognized or how they are measured have not changed. This amendment only impacts where those costs are reflected within the income statement. In addition, only the service cost component will be eligible for capitalization in inventory and other assets. This guidance became effective January 1, 2018. The adoption of this new standard did not have a material impact on the Company’s consolidated financial statements.  In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force (the “Task Force”). The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. This update is effective for years beginning after December 31, 2018. The Company has restricted cash balances and anticipates that the adoption of this new standard will change the cash amounts and financing activities on its statement of cash flows on its consolidated financial statements. In February 2016, the FASB issued its final standard on accounting for leases. This standard, issued as ASU 2016-02, requires that an entity that is a lessee to recognize lease assets and lease liabilities on the balance sheet for all leases and disclose key information about leasing arrangements. This update is effective for financial statement periods beginning after December 15, 2018, with earlier application permitted. The Company has not yet determined the impact of this pronouncement on its consolidated financial statements and related disclosures, but anticipates it will be required to record additional lease liabilities and corresponding rights to use assets.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2018
Discontinued Operations [Abstract]
Summary Of Balance Sheet And Results Of Discontinued Operations	   The following table shows the results of the cardiac diagnostic monitoring discontinued operations:     Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017  Sales, net $ - $ - $ - $ 140  Operating costs and expenses - (15) - (268)  Net loss from discontinued operations - (15) - (128)   The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC for a future revenue earn-out that was valued by the Company at $0 . The Company has not earned any earn-out revenue through June 30, 2018. The Company recorded a loss on the sale of $164 . The net loss was computed as follows:     Accounts receivable, net $ 179  Accrued liabilities (15)  Net assets sold $ 164  Fair value of consideration received -  Loss on sale of discontinued operations, net of income taxes $ 164 

Significant Changes Due To To27

Significant Changes Due To Topic 606 (Tables)	6 Months Ended
	Jun. 30, 2018
Significant Changes Due To Topic 606 [Abstract]
Summary of the Effects of Adoption of ASC Topic 606 on the Company's unaudited Consolidated Financial Statements	Consolidated Statement of Operations:     Three Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Three Months Ended June 30, 2017, as adjusted Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Sales, net $ 21,961 $ 563 $ 22,524 $ 42,049 $ 1,690 $ 43,739  Cost of sales 15,380 505 15,885 29,792 1,474 31,266  Gross profit 6,581 58 6,639 12,257 216 12,473   Operating expenses:  Sales and marketing 2,204 - 2,204 4,515 - 4,515  General and administrative 2,705 - 2,705 5,263 - 5,263  Research and development 1,112 - 1,112 2,265 - 2,265  Total operating expenses 6,021 - 6,021 12,043 - 12,043  Operating income (loss) 560 58 618 214 216 430   Interest expense (189) - (189) (371) - (371)  Other income (47) - (47) 9 - 9  Income (loss) from continuing operations before income taxes and discontinued operations 324 58 382 (148) 216 68  Income tax expense 54 - 54 118 - 118  Income (loss) from continuing operations before discontinued operations 270 58 328 (266) 216 (50)  Loss on sale of discontinued operations (Note 3) - - - (164) - (164)  Loss from discontinued operations (Note 3) (15) - (15) (128) - (128)  Net income (loss) 255 58 313 (558) 216 (342)  Less: Loss allocated to non-controlling interest (355) - (355) (740) - (740)  Net income (loss) attributable to IntriCon shareholders $ 610 $ 58 $ 668 $ 182 $ 216 $ 398   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.09 $ 0.01 $ 0.10 $ 0.07 $ 0.03 $ 0.10  Discontinued operations - - $ - (0.04) - (0.04)  Net income (loss) per share: $ 0.09 $ 0.01 $ 0.10 $ 0.03 $ 0.03 $ 0.06   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.09 $ 0.01 $ 0.10 $ 0.07 $ 0.03 $ 0.10  Discontinued operations - - - (0.04) - (0.04)  Net income (loss) per share: $ 0.08 $ 0.01 $ 0.09 $ 0.03 $ 0.03 $ 0.06   Average shares outstanding:  Basic 6,845 6,845 6,845 6,828 6,828 6,828  Diluted 7,187 7,187 7,187 6,828 6,828 6,828   Consolidated Statement of Comprehensive Income (Loss):     Three Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Three Months Ended June 30, 2017, as adjusted   Net income $ 255 $ 58 $ 313   Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Net income (loss) $ (558) $ 216 $ (342)  Consolidated Statement of Cash Flows:    Six Months Ended June 30, 2017, as reported Effect of Adoption of ASC 606 Six Months Ended June 30, 2017, as adjusted   Net income (loss) $ (558) $ 216 $ (342)  Inventories (1,662) 466 (1,196)  Contract assets - (682) (682)  Prior Year Consolidated Balance Sheet:     December 31, 2017, as reported Effect of Adoption of ASC 606 December 31, 2017, as adjusted   Inventories $ 15,397 $ (1,689) $ 13,708  Contract assets - 2,979 2,979  Other accrued liabilities 3,224 515 3,739  Accumulated deficit (6,831) 775 (6,056) 
Summary of Information about Receivables, Contracts Assets, and Contract Liabilities from Contracts with Customers	   June 30, 2018 December 31, 2017, as adjusted   Receivables, included in accounts receivable, less allowance for doubtful account $ 10,067 $ 9,052  Contract assets 6,032 2,979  Contract liabilities, included in other current liabilities 402 312  Significant changes in contract assets and contract liabilities during the period are as follows:    For the six months ended June 30, 2018  Contract assets increase (decrease) Contract liabilities (increase) decrease   Reclassification of beginning contract liabilities to revenue, as a result of performance obligations satisfied $ - $ 312  Cash received in advance and not recognized as revenue - (402)  Reclassification of beginning contract assets to accounts receivable, as a result of right to consideration becoming unconditional - -  Contract assets recognized, net of reclassification to accounts receivable 3,053  Cumulative catch-up from a change in the timeframe for recognition of revenue arising from a contract liability - -  Increase as a result of cumulative catch-up adjustment arising from changes in the estimate of costs incurred relative to total amounts projected, excluding amounts transferred to receivables during the period. -  Net Change $ 3,053 $ (90) 

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting, Geographic Information [Abstract]
Summary Of Data By Industry Segment	  At and for the Three Months Ended June 30, 2018 Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 28,108 $ 2,052 $ 30,160  Income (loss) from continuing operations 2,509 (501) 2,008  Identifiable assets (excluding goodwill) 46,173 5,994 52,167  Goodwill 9,551 1,257 10,808  Depreciation and amortization 727 51 778  Capital expenditures 1,067 56 1,123   At and for the Six Months Ended June 30, 2018 Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 51,680 $ 3,843 $ 55,523  Income (loss) from continuing operations 3,729 (954) 2,775  Identifiable assets (excluding goodwill) 46,173 5,994 52,167  Goodwill 9,551 1,257 10,808  Depreciation and amortization 1,332 100 1,432  Capital expenditures 1,542 66 1,608   At and for the Three Months Ended June 30, 2017 (as adjusted) Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 21,115 $ 1,409 $ 22,524  Income (loss) from continuing operations 753 (425) 328  Identifiable assets (excluding goodwill) 31,613 4,467 36,080  Goodwill 9,551 1,004 10,555  Depreciation and amortization 499 44 543  Capital expenditures 273 72 345   At and for the Six Months Ended June 30, 2017 (as adjusted) Body Worn Devices Hearing Health Direct-to-End-Consumer Total  Revenue, net $ 40,914 $ 2,825 $ 43,739  Income (loss) from continuing operations 828 (878) (50)  Identifiable assets (excluding goodwill) 31,613 4,467 36,080  Goodwill 9,551 1,004 10,555  Depreciation and amortization 994 111 1,105  Capital expenditures 486 132 618 

Geographic Information (Tables)

Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting, Geographic Information [Abstract]
Geographical Distribution Of Long-Lived Assets, Net	   June 30, December 31,  2018 2017  United States $ 7,513 $ 5,407  Singapore 1,143 1,254  Other – primarily United Kingdom and Indonesia 497 514  Consolidated $ 9,153 $ 7,175 
Geographical Distribution Of Net Sales	   Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 (as adjusted) June 30, 2018 June 30, 2017 (as adjusted)  United States $ 25,255 $ 18,239 $ 45,714 $ 34,889  Europe 1,884 2,307 4,162 4,785  Asia 2,699 1,891 5,167 3,801  All other countries 322 87 480 264  Consolidated $ 30,160 $ 22,524 $ 55,523 $ 43,739 

Investment In Partnerships (Tab

Investment In Partnerships (Tables)	6 Months Ended
	Jun. 30, 2018
Investment In Partnerships [Abstract]
Investments in Partnerships	  June 30, December 31,  2018 2017  Investment in Soundperience $ 1,091 $ 842  Investment in Signison 539 498  Other 235 276  Total $ 1,865 $ 1,616 

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2018
Inventories [Abstract]
Schedule Of Inventories	   Raw materials Work-in process Finished products and components Total  June 30, 2018  Domestic $ 8,148 $ 2,080 $ 1,216 $ 11,444  Foreign 2,231 1,039 930 4,200  Total $ 10,379 $ 3,119 $ 2,146 $ 15,644   December 31, 2017 (as adjusted)  Domestic $ 6,924 $ 1,791 $ 1,366 $ 10,081  Foreign 2,258 514 855 3,627  Total $ 9,182 $ 2,305 $ 2,221 $ 13,708 

Short And Long-Term Debt (Table

Short And Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Short And Long-Term Debt [Abstract]
Summary Of Short And Long-Term Debt	   June 30, December 31,  2018 2017   Domestic Asset-Based Revolving Credit Facility $ 6,394 $ 4,000  Capital expenditure loan facility - -  Foreign Overdraft and Letter of Credit Facility 1,241 1,250  Domestic Term-Loan 5,750 6,250  Unamortized Finance Costs (108) (139)  Total Debt 13,277 11,361  Less: Current maturities (2,072) (2,040)  Total Long-Term Debt $ 11,205 $ 9,321 

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2018
Income Taxes [Abstract]
Income (Loss) Before Income Taxes For Each Jurisdiction	   Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017  United States $ 2,450 $ 486 $ 3,299 $ 257  Singapore 98 16 346 (77)  Indonesia 21 18 42 34  United Kingdom (334) (286) (570) (411)  Germany 42 148 113 265  Income (loss) before income taxes $ 2,277 $ 382 $ 3,230 $ 68 

Shareholders' Equity And Stoc34

Shareholders' Equity And Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Shareholders' Equity And Stock-Based Compensation [Abstract]
Summary Of Award Activity	    Outstanding Awards Weighted-average Aggregate  Stock Options RSUs Total Exercise Price (a) Intrinsic Value   Outstanding at December 31, 2017 1,453 - 1,453 $ 5.95  Forfeited, cancelled or expired (18) - (18) 7.93  Granted - 98 98 -  Exercised (186) - (186) 6.23   Outstanding at June 30, 2018 1,249 98 1,347 $ 5.52 $ 46,832   Exercisable at June 30, 2018 964 - 964 $ 5.58 $ 33,479   Available for future grant at December 31, 2017 251   Available for future grant at June 30, 2018 215   (a) The weighted average exercise price calculation does not include outstanding RSUs. 

Income (Loss) Per Share (Tables

Income (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Income (Loss) Per Share [Abstract]
Reconciliation Between Basic And Diluted Earnings Per Share	   Three Months Ended Six Months Ended  June 30, 2018 June 30, 2017 (as adjusted) June 30, 2018 June 30, 2017 (as adjusted)  Numerator:  Income (loss) from continuing operations before discontinued operations $ 2,008 $ 328 $ 2,775 $ (50)  Loss on sale of discontinued operations - - - (164)  Loss from discontinued operations, net of income taxes - (15) - (128)   Net income (loss) 2,008 313 2,775 (342)   Less: loss allocated to non-controlling interest - (355) - (740)   Net income (loss) attributable to shareholders $ 2,008 $ 668 $ 2,775 $ 398   Denominator:  Basic – weighted shares outstanding 6,991 6,845 6,930 6,828  Weighted shares assumed upon exercise of stock options 1,127 342 1,091 -  Diluted – weighted shares outstanding 8,118 7,187 8,021 6,828   Basic income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.29 $ 0.10 $ 0.40 $ 0.10  Discontinued operations - - - (0.04)  Net income (loss) per share: $ 0.29 $ 0.10 $ 0.40 $ 0.06   Diluted income (loss) per share attributable to IntriCon shareholders:  Continuing operations $ 0.25 $ 0.10 $ 0.35 0.10  Discontinued operations - - - (0.04)  Net income (loss) per share: $ 0.25 $ 0.09 $ 0.35 $ 0.06 

Revenue By Market (Tables)

Revenue By Market (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue By Market [Abstract]
Schedule Of Net Revenue By Market	  Timing of revenue recognition for the three months ended June 30, 2018:  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 20,198 $ 20,198  Hearing Health 6,390 - 6,390  Professional Audio Communications 1,520 - 1,520  Hearing Health DTEC Segment:  Hearing Health DTEC 2,052 - 2,052  Total Revenue $ 9,962 $ 20,198 $ 30,160   Timing of revenue recognition for the six months ended June 30, 2018:  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 36,131 $ 36,131  Hearing Health 12,200 - 12,200  Professional Audio Communications 3,349 - 3,349  Hearing Health DTEC Segment:  Hearing Health DTEC 3,843 - 3,843  Total Revenue $ 19,392 $ 36,131 $ 55,523   Timing of revenue recognition for the three months ended June 30, 2017 (as adjusted):   Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 13,572 $ 13,572  Hearing Health 6,035 - 6,035  Professional Audio Communications 1,508 - 1,508  Hearing Health DTEC Segment:  Hearing Health DTEC 1,409 - 1,409  Total Revenue $ 8,952 $ 13,572 $ 22,524   Timing of revenue recognition for the six months ended June 30, 2017 (as adjusted):  Products and services transferred at point in time Products and services transferred over time Total  Body Worn Devices Segment:  Medical $ - $ 25,752 $ 25,752  Hearing Health 12,272 - 12,272  Professional Audio Communications 2,890 - 2,890  Hearing Health DTEC Segment:  Hearing Health DTEC 2,825 - 2,825  Total Revenue $ 17,987 $ 25,752 $ 43,739 

General (Narrative) (Details)

General (Narrative) (Details) - 6 months ended Jun. 30, 2018 € in Thousands, $ in Thousands	USD ($)	EUR (€)	USD ($)
Hearing Help Express (HHE) [Member]
Additional percentage acquired	80.00%
Purchase price, paid in cash	$ 650
Repayment in debt to HHE's 80% holder			$ 1,833
Percentage ownership after transaction	100.00%
Soundperience GmbH [Member]
Additional percentage acquired	33.00%
Percentage ownership after transaction	49.00%
Equity method investment | €		€ 1,500

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($)	Feb. 17, 2017	Jun. 30, 2017
Loss on sale of discontinued operations, net of income taxes		$ 164,000
Cardiac Diagnostic Monitoring Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Future revenue earn-out	$ 0
Loss on sale of discontinued operations, net of income taxes	$ 164,000

Discontinued Operations (Summar

Discontinued Operations (Summary Of Results Of Discontinued Operations) (Details) - Cardiac Diagnostic Monitoring Business [Member] - Discontinued Operations, Disposed of by Sale [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Sales, net		$ 140
Operating costs and expenses	$ (15)	(268)
Net loss from discontinued operations	$ (15)	$ (128)

Discontinued Operations (Schedu

Discontinued Operations (Schedule Of Loss On Sale Of Discontinued Operations) (Details) - USD ($) $ in Thousands	Feb. 17, 2017	Jun. 30, 2017
Loss on sale of discontinued operations, net of income taxes		$ 164
Discontinued Operations, Disposed of by Sale [Member] | Cardiac Diagnostic Monitoring Business [Member]
Accounts receivable, net	$ 179
Accrued liabilities	(15)
Net assets sold	164
Fair value of consideration received
Loss on sale of discontinued operations, net of income taxes	$ 164

Changes In Accounting Policies

Changes In Accounting Policies (Narrative) (Details)	6 Months Ended
	Jun. 30, 2018
Hearing Health Direct-to-End Consumer (DTEC) Market [Member]
Trial period	60 days

Significant Changes Due To To42

Significant Changes Due To Topic 606 (Narrative) (Details) $ in Thousands	Jan. 01, 2017USD ($)
Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	$ 518

Significant Changes Due To To43

Significant Changes Due To Topic 606 (Summary of the Effects of Adoption of ASC Topic 606 on the Company's unaudited Consolidated Statements of Operations) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Sales, net	$ 30,160	$ 22,524	$ 55,523	$ 43,739
Cost of sales	20,171	15,885	37,122	31,266
Gross profit	9,989	6,639	18,401	12,473
Operating expenses:
Sales and marketing	2,881	2,204	5,721	4,515
General and administrative	3,108	2,705	6,169	5,263
Research and development	1,316	1,112	2,475	2,265
Total operating expenses	7,305	6,021	14,365	12,043
Operating income	2,684	618	4,036	430
Interest expense	(211)	(189)	(405)	(371)
Other income	(196)	(47)	(401)	9
Income from continuing operations before income taxes and discontinued operations	2,277	382	3,230	68
Income tax expense	269	54	455	118
Income (loss) from continuing operations before discontinued operations	2,008	328	2,775	(50)
Loss on sale of discontinued operations (Note 3)				(164)
Loss from discontinued operations (Note 3)		(15)		(128)
Net income (loss)	2,008	313	2,775	(342)
Less: Loss allocated to non-controlling interest		(355)		(740)
Net income attributable to IntriCon shareholders	$ 2,008	$ 668	$ 2,775	$ 398
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$ 0.29	$ 0.10	$ 0.40	$ 0.10
Discontinued operations				(0.04)
Net income (loss) per share:	0.29	0.10	0.40	0.06
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations	0.25	0.10	0.35	0.10
Discontinued operations				(0.04)
Net income (loss) per share:	$ 0.25	$ 0.09	$ 0.35	$ 0.06
Average shares outstanding:
Basic	6,991	6,845	6,930	6,828
Diluted	8,118	7,187	8,021	6,828
Accounting Standards Update 2014-09 [Member]
Sales, net		$ 22,524		$ 43,739
Cost of sales		15,885		31,266
Gross profit		6,639		12,473
Operating expenses:
Sales and marketing		2,204		4,515
General and administrative		2,705		5,263
Research and development		1,112		2,265
Total operating expenses		6,021		12,043
Operating income		618		430
Interest expense		(189)		(371)
Other income		(47)		9
Income from continuing operations before income taxes and discontinued operations		382		68
Income tax expense		54		118
Income (loss) from continuing operations before discontinued operations		328		(50)
Loss on sale of discontinued operations (Note 3)				(164)
Loss from discontinued operations (Note 3)		(15)		(128)
Net income (loss)		313		(342)
Less: Loss allocated to non-controlling interest		(355)		(740)
Net income attributable to IntriCon shareholders		$ 668		$ 398
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations		$ 0.10		$ 0.10
Discontinued operations				(0.04)
Net income (loss) per share:		0.10		0.06
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations		0.10		0.10
Discontinued operations				(0.04)
Net income (loss) per share:		$ 0.09		$ 0.06
Average shares outstanding:
Basic		6,845		6,828
Diluted		7,187		6,828
Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Sales, net		$ 563		$ 1,690
Cost of sales		505		1,474
Gross profit		58		216
Operating expenses:
Operating income		58		216
Income from continuing operations before income taxes and discontinued operations		58		216
Income (loss) from continuing operations before discontinued operations		58		216
Net income (loss)		58		216
Net income attributable to IntriCon shareholders		$ 58		$ 216
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations		$ 0.01		$ 0.03
Net income (loss) per share:		0.01		0.03
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations		0.01		0.03
Net income (loss) per share:		$ 0.01		$ 0.03
Average shares outstanding:
Basic		6,845		6,828
Diluted		7,187		6,828
Accounting Standards Update 2014-09 [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Sales, net		$ 21,961		$ 42,049
Cost of sales		15,380		29,792
Gross profit		6,581		12,257
Operating expenses:
Sales and marketing		2,204		4,515
General and administrative		2,705		5,263
Research and development		1,112		2,265
Total operating expenses		6,021		12,043
Operating income		560		214
Interest expense		(189)		(371)
Other income		(47)		9
Income from continuing operations before income taxes and discontinued operations		324		(148)
Income tax expense		54		118
Income (loss) from continuing operations before discontinued operations		270		(266)
Loss on sale of discontinued operations (Note 3)				(164)
Loss from discontinued operations (Note 3)		(15)		(128)
Net income (loss)		255		(558)
Less: Loss allocated to non-controlling interest		(355)		(740)
Net income attributable to IntriCon shareholders		$ 610		$ 182
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations		$ 0.09		$ 0.07
Discontinued operations				(0.04)
Net income (loss) per share:		0.09		0.03
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations		0.09		0.07
Discontinued operations				(0.04)
Net income (loss) per share:		$ 0.08		$ 0.03
Average shares outstanding:
Basic		6,845		6,828
Diluted		7,187		6,828

Significant Changes Due To To44

Significant Changes Due To Topic 606 (Summary of the Effects of Adoption of ASC Topic 606 on the Company's unaudited Consolidated Statement of Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net income (loss)	$ 2,008	$ 313	$ 2,775	$ (342)
Accounting Standards Update 2014-09 [Member]
Net income (loss)		313		(342)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Net income (loss)		58		216
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Net income (loss)		$ 255		$ (558)

Significant Changes Due To To45

Significant Changes Due To Topic 606 (Summary of the Effects of Adoption of ASC Topic 606 on the Company's unaudited Consolidated Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net income (loss)	$ 2,008	$ 313	$ 2,775	$ (342)
Inventories			(1,918)	(1,196)
Contract assets			$ (3,053)	(682)
Accounting Standards Update 2014-09 [Member]
Net income (loss)		313		(342)
Inventories				(1,196)
Contract assets				(682)
Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Net income (loss)		58		216
Inventories				466
Contract assets				(682)
Accounting Standards Update 2014-09 [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Net income (loss)		$ 255		(558)
Inventories				$ (1,662)

Significant Changes Due To To46

Significant Changes Due To Topic 606 (Summary of the Effects of Adoption of ASC Topic 606 on the Company's Prior Year Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventories	$ 15,644	$ 13,708
Contract assets	6,032	2,979
Other accrued liabilities	3,552	3,739
Accumulated deficit	$ (3,281)	(6,056)
Accounting Standards Update 2014-09 [Member]
Inventories		13,708
Contract assets		2,979
Other accrued liabilities		3,739
Accumulated deficit		(6,056)
Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Inventories		(1,689)
Contract assets		2,979
Other accrued liabilities		515
Accumulated deficit		775
Accounting Standards Update 2014-09 [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Inventories		15,397
Other accrued liabilities		3,224
Accumulated deficit		$ (6,831)

Significant Changes Due To To47

Significant Changes Due To Topic 606 (Summary of Information about Receivables, Contracts Assets, and Contract Liabilities from Contracts with Customers) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Significant Changes Due To Topic 606 [Abstract]
Receivables, included in "accounts receivable, less allowance for doubtful accounts"	$ 10,067	$ 9,052
Contract assets, included in other current assets	6,032	2,979
Contract liabilities, included in other current liabilities	$ 402	$ 312

Significant Changes Due To To48

Significant Changes Due To Topic 606 (Significant Changes in Contract Assets and Contract Liabilities) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Significant Changes Due To Topic 606 [Abstract]
Reclassification of beginning contract liabilities to revenue, as a result of performance obligations satisfied	$ 312
Cash received in advance and not recognized as revenue	(402)
Contract assets recognized, net of reclassification to accounts receivable	3,053
Net Change in Contract Asset	3,053	$ 682
Net Change in Contract Liability	$ (90)

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	6 Months Ended
	Jun. 30, 2018segment
Segment Reporting, Geographic Information [Abstract]
Number of reportable segments	2

Segment Reporting (Summary Of D

Segment Reporting (Summary Of Data By Industry Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Sales, net	$ 30,160	$ 22,524	$ 55,523	$ 43,739
Income (loss) from continuing operations	2,008	328	2,775	(50)
Identifiable assets (excluding goodwill)	52,167	36,080	52,167	36,080
Goodwill	10,808	10,555	10,808	10,555	$ 10,808
Depreciation and amortization	778	543	1,432	1,105
Capital expenditures	1,123	345	1,608	618
Body Worn Devices Segment [Member]
Sales, net	28,108	21,115	51,680	40,914
Income (loss) from continuing operations	2,509	753	3,729	828
Identifiable assets (excluding goodwill)	46,173	31,613	46,173	31,613
Goodwill	9,551	9,551	9,551	9,551
Depreciation and amortization	727	499	1,332	994
Capital expenditures	1,067	273	1,542	486
Hearing Health Direct-to-End Consumer [Member]
Sales, net	2,052	1,409	3,843	2,825
Income (loss) from continuing operations	(501)	(425)	(954)	(878)
Identifiable assets (excluding goodwill)	5,994	4,467	5,994	4,467
Goodwill	1,257	1,004	1,257	1,004
Depreciation and amortization	51	44	100	111
Capital expenditures	$ 56	$ 72	$ 66	$ 132

Geographic Information (Narrati

Geographic Information (Narrative) (Details) - customer	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Net Sales [Member] | One Customer [Member]
Revenue, Major Customer [Line Items]
Number of customers	1	1	1	1
Percentage of risk	57.00%	49.00%	56.00%	47.00%
Accounts Receivable [Member] | Two Customers [Member]
Revenue, Major Customer [Line Items]
Number of customers			2		2
Percentage of risk			35.00%		32.00%
Contract Assets [Member] | One Customer [Member]
Revenue, Major Customer [Line Items]
Percentage of risk			77.00%		62.00%

Geographic Information (Geograp

Geographic Information (Geographical Distribution Of Long-Lived Assets, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 9,153	$ 7,175
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	7,513	5,407
Singapore [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	1,143	1,254
Other-Primarily United Kingdom And Indonesia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 497	$ 514

Geographic Information (Geogr53

Geographic Information (Geographical Distribution Of Net Sales) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 30,160	$ 22,524	$ 55,523	$ 43,739
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	25,255	18,239	45,714	34,889
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,884	2,307	4,162	4,785
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	2,699	1,891	5,167	3,801
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 322	$ 87	$ 480	$ 264

Investment In Partnerships (Nar

Investment In Partnerships (Narrative) (Details)	6 Months Ended
	Jun. 30, 2018
Soundperience GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Additional percentage acquired	33.00%
Percentage ownership after transaction	49.00%
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Equity method, ownership interest	50.00%

Investment In Partnerships (Inv

Investment In Partnerships (Investments in Partnerships) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]
Other	$ 235	$ 276
Total	1,865	1,616
Soundperience GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	1,091	842
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 539	$ 498

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 10,379	$ 9,182
Work-in process	3,119	2,305
Finished products and components	2,146	2,221
Total	15,644	13,708
Domestic [Member]
Inventory [Line Items]
Raw materials	8,148	6,924
Work-in process	2,080	1,791
Finished products and components	1,216	1,366
Total	11,444	10,081
Foreign [Member]
Inventory [Line Items]
Raw materials	2,231	2,258
Work-in process	1,039	514
Finished products and components	930	855
Total	$ 4,200	$ 3,627

Short And Long-Term Debt (Narra

Short And Long-Term Debt (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Short And Long-Term Debt Instrument [Line Items]
Inventory cap on borrowing base			$ 4,500,000
Annual capital expenditure allowed			5,500,000
Interest expense	$ 211,000	$ 189,000	405,000	$ 371,000
Domestic Term-Loan [Member]
Short And Long-Term Debt Instrument [Line Items]
Loan amount	6,500,000		6,500,000
Quarterly installments			$ 250,000
Percentage of proceeds from certain asset sales required to pay down term loan			100.00%
Debt	5,750,000		$ 5,750,000		$ 6,250,000
Domestic Asset-based Revolving Credit Facility [Member]
Short And Long-Term Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 9,000,000		$ 9,000,000
Weighted average interest rate of debt instruments	5.25%		5.25%		5.11%
Debt	$ 6,394,000		$ 6,394,000		$ 4,000,000
Letters Of Credit [Member]
Short And Long-Term Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	200,000		200,000
Capital Expenditure Loan Facility [Member]
Short And Long-Term Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	2,500,000		2,500,000
Debt
Foreign Overdraft And Letter Of Credit Facility [Member]
Short And Long-Term Debt Instrument [Line Items]
Weighted average interest rate of debt instruments	4.30%		4.30%		3.87%
Debt	$ 1,241,000		$ 1,241,000		$ 1,250,000
Foreign Overdraft And Letter Of Credit Facility [Member] | Minimum [Member]
Short And Long-Term Debt Instrument [Line Items]
Interest rate of debt instruments	0.75%		0.75%
Foreign Overdraft And Letter Of Credit Facility [Member] | Maximum [Member]
Short And Long-Term Debt Instrument [Line Items]
Interest rate of debt instruments	2.50%		2.50%

Short And Long-Term Debt (Summa

Short And Long-Term Debt (Summary Of Short And Long-Term Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Unamortized Finance Costs	$ (108)	$ (139)
Total Debt	13,277	11,361
Less: Current maturities	(2,072)	(2,040)
Total long-term debt	11,205	9,321
Domestic Term-Loan [Member]
Debt Instrument [Line Items]
Debt	5,750	6,250
Domestic Asset-based Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt	6,394	4,000
Capital Expenditure Loan Facility [Member]
Debt Instrument [Line Items]
Debt
Foreign Overdraft And Letter Of Credit Facility [Member]
Debt Instrument [Line Items]
Debt	$ 1,241	$ 1,250

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Taxes [Abstract]
Income tax expense	$ 269	$ 54	$ 455	$ 118

Income Taxes (Income (Loss) Bef

Income Taxes (Income (Loss) Before Income Taxes For Each Jurisdiction) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Loss Carryforwards [Line Items]
Income from continuing operations before income taxes and discontinued operations	$ 2,277	$ 382	$ 3,230	$ 68
United States IRS [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes, United States	2,450	486	3,299	257
Singapore Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes, Foreign	98	16	346	(77)
Indonesia [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes, Foreign	21	18	42	34
United Kingdom [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes, Foreign	(334)	(286)	(570)	(411)
Germany [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes, Foreign	$ 42	$ 148	$ 113	$ 265

Shareholders' Equity And Stoc61

Shareholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	215		215			251
Number of Shares, Options granted			98
Stock option expense	$ 333	$ 207	$ 667	$ 425
Unrecognized compensation costs related to non-vested awards	$ 2,639		$ 2,639
Unrecognized compensation costs related to non-vested awards, recognition period			2 years 3 months 11 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Number of Shares, Options granted	11		98
Share Price	$ 20.61		$ 20.61		$ 23.50
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted	763		763
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased for award	1	3	4	7
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options			10 years
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares approved under purchase plan	300		300

Shareholders' Equity And Stoc62

Shareholders' Equity And Stock-Based Compensation (Schedule Of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares
Number of Shares, Outstanding		1,453
Number of Shares, Options forfeited or cancelled		(18)
Number of Shares, Options granted		98
Number of Shares, Options exercised		(186)
Number of Shares, Outstanding	1,347	1,347
Number of Shares, Exercisable	964	964
Number of Shares, Available for future grant at beginning of period		251
Number of Shares, Available for future grant at end of period	215	215
Weighted-average Exercise Price, Outstanding | $ / shares		$ 5.95
Weighted-average Exercise Price, Options forfeited or cancelled | $ / shares		7.93
Weighted-average Exercise Price, Options exercised | $ / shares		6.23
Weighted-average Exercise Price, Outstanding | $ / shares	$ 5.52	5.52
Weighted-average Exercise Price, Exercisable | $ / shares	$ 5.58	$ 5.58
Aggregate Intrinsic Value, Outstanding | $	$ 46,832	$ 46,832
Aggregate Intrinsic Value, Exercisable | $	$ 33,479	$ 33,479
Stock Options [Member]
Number of Shares, Outstanding		1,453
Number of Shares, Options forfeited or cancelled		(18)
Number of Shares, Options exercised		(186)
Number of Shares, Outstanding	1,249	1,249
Number of Shares, Exercisable	964	964
Restricted Stock Units (RSUs) [Member]
Number of Shares, Options granted	11	98
Number of Shares, Outstanding	98	98

Income (Loss) Per Share (Narrat

Income (Loss) Per Share (Narrative) (Details) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Income (Loss) Per Share [Abstract]
Securities excluded from computation of diluted income per share	0	0	314

Income (Loss) Per Share (Reconc

Income (Loss) Per Share (Reconciliation Between Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income (Loss) Per Share [Abstract]
Income (loss) from continuing operations before income taxes and discontinued operations	$ 2,008	$ 328	$ 2,775	$ (50)
Loss on sale of discontinued operations				(164)
Loss from discontinued operations, net of income taxes		(15)		(128)
Net income (loss)	2,008	313	2,775	(342)
Less: Loss allocated to non-controlling interest		(355)		(740)
Net income attributable to IntriCon shareholders	$ 2,008	$ 668	$ 2,775	$ 398
Basic - weighted shares outstanding	6,991	6,845	6,930	6,828
Weighted shares assumed upon exercise of stock options	1,127	342	1,091
Diluted - weighted shares outstanding	8,118	7,187	8,021	6,828
Continuing operations	$ 0.29	$ 0.10	$ 0.40	$ 0.10
Discontinued operations				(0.04)
Net income (loss) per share:	0.29	0.10	0.40	0.06
Continuing operations	0.25	0.10	0.35	0.10
Discontinued operations				(0.04)
Net income (loss) per share:	$ 0.25	$ 0.09	$ 0.35	$ 0.06

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Thousands	Jun. 30, 2018USD ($)
Legal Proceedings [Abstract]
Selas SAS, Liabilities	$ 456

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Related-Party Transactions [Abstract]
Legal services and costs	$ 72	$ 27	$ 175	$ 66

Revenue By Market (Schedule Of

Revenue By Market (Schedule Of Net Revenue By Market)(Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue, Major Customer [Line Items]
Total Revenue	$ 30,160	$ 22,524	$ 55,523	$ 43,739
Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	9,962	8,952	19,392	17,987
Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	20,198	13,572	36,131	25,752
Body Worn Devices Segment [Member]
Revenue, Major Customer [Line Items]
Total Revenue	28,108	21,115	51,680	40,914
Hearing Health Direct-to-End Consumer [Member]
Revenue, Major Customer [Line Items]
Total Revenue	2,052	1,409	3,843	2,825
Medical [Member] | Body Worn Devices Segment [Member]
Revenue, Major Customer [Line Items]
Total Revenue	20,198	13,572	36,131	25,752
Medical [Member] | Body Worn Devices Segment [Member] | Products and Services Transferred over Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	20,198	13,572	36,131	25,752
Hearing Health Market [Member] | Body Worn Devices Segment [Member]
Revenue, Major Customer [Line Items]
Total Revenue	6,390	6,035	12,200	12,272
Hearing Health Market [Member] | Body Worn Devices Segment [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	6,390	6,035	12,200	12,272
Professional Audio Communications [Member] | Body Worn Devices Segment [Member]
Revenue, Major Customer [Line Items]
Total Revenue	1,520	1,508	3,349	2,890
Professional Audio Communications [Member] | Body Worn Devices Segment [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	1,520	1,508	3,349	2,890
Hearing Health Direct-to-End Consumer (DTEC) Market [Member] | Hearing Health Direct-to-End Consumer [Member]
Revenue, Major Customer [Line Items]
Total Revenue	2,052	1,409	3,843	2,825
Hearing Health Direct-to-End Consumer (DTEC) Market [Member] | Hearing Health Direct-to-End Consumer [Member] | Products and Services Transferred at Point in Time [Member]
Revenue, Major Customer [Line Items]
Total Revenue	$ 2,052	$ 1,409	$ 3,843	$ 2,825

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jul. 23, 2018	Jun. 30, 2018	Dec. 31, 2019
Subsequent Event [Line Items]
Inventory cap on borrowing base		$ 4,500,000
Annual capital expenditure allowed		5,500,000
Scenario, Plan [Member]
Subsequent Event [Line Items]
Annual capital expenditure allowed			$ 5,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Inventory cap on borrowing base	$ 5,000,000
Annual capital expenditure allowed	$ 12,000,000
Increase (Decrease) In Applicable Interest Rates	(0.25%)
Domestic Asset-based Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		9,000,000
Domestic Asset-based Revolving Credit Facility [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 11,000,000
Capital Expenditure Loan Facility [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,500,000
Capital Expenditure Loan Facility [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 10,000,000